At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 330 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
In Brief
A Phase 3 clinical trial evaluating Ruxolitinib cream and Vehicle for Non-segmental Vitiligo. Completed, enrolled 330 participants across 57 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-segmental Vitiligo
CountriesBulgaria, Canada, France, Germany, Italy, Poland, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartSep 2019
Primary CompletionMar 2021
Study CompletionOct 2021
TodayJul 2026
First PostedAug 9, 2019
Enrollment StartSep 20, 2019
Primary CompletionMar 18, 2021
Study CompletionOct 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.9 years ago
Interventions
Ruxolitinib creamdrug
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Vehicledrug
Vehicle cream is a topical formulation applied as a thin film to affected areas.